FDA Panel Rejects Combo Drug for PTSD
An FDA advisory panel has resoundingly rejected the supplemental new drug application for the atypical antipsychotic brexpiprazole (Rexulti,…
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a…
New Clozapine Consensus Guidelines Drop ANC Monitoring
Monitoring absolute neutrophil count (ANC) levels beyond 2 years of clozapine treatment is no longer necessary, new international…